Related Experiment Video

Updated: May 20, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of

Magdalena Winiarska1, Dominika Nowis, Jacek Bil

  • 1Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland.

The Journal of Biological Chemistry
|July 31, 2012
PubMed

Insights

Farnesyltransferase inhibitors (FTIs) increase CD20 expression and enhance the effectiveness of anti-CD20 monoclonal antibodies (mAbs) against B-cell tumors. This combination therapy shows promise for treating non-Hodgkin lymphomas and chronic lymphocytic leukemia.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Anti-CD20 monoclonal antibodies (mAbs) are established treatments for B-cell malignancies like non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL).
  • Previous research indicated statins can alter CD20 conformation, impacting rituximab efficacy.

Purpose of the Study:

  • To investigate the effect of farnesyltransferase inhibitors (FTIs) on CD20 expression.
  • To evaluate the impact of FTIs on the antitumor activity of anti-CD20 mAbs.

Main Methods:

  • Treatment of lymphoma and leukemia cells with various FTIs, including L-744,832.
  • Assessment of CD20 expression levels via mRNA and protein analysis.
  • Measurement of rituximab-mediated complement-dependent cytotoxicity (CDC).
  • Chromatin immunoprecipitation (ChIP) assays to analyze transcription factor binding to the CD20 promoter.

Main Results:

  • L-744,832 demonstrated the most significant impact on CD20 levels among tested FTIs.
  • L-744,832 increased CD20 expression in most primary patient samples and Raji cells.
  • Enhanced rituximab-mediated CDC against primary tumor cells was observed.
  • FTI treatment led to increased binding of PU.1 and Oct-2 to CD20 promoter regions.

Conclusions:

  • Farnesyltransferase inhibition modulates CD20 expression.
  • Combining FTIs with anti-CD20 mAbs represents a promising therapeutic strategy for B-cell tumors.
  • Further clinical investigation of FTI and anti-CD20 mAb combination therapy is warranted.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Murine Model of CD40-activation of B cells12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.